Involvement of the thalamocortical network in TLE with and without mesiotemporal sclerosis
Susanne G. Mueller(University of California, San Francisco), Michael W. Weiner(University of California, San Francisco), Valerie Cardenas‐Nicolson(Institute for Neurodegenerative Disorders), Jerome Barakos(Sutter Health), Ian Cheong(Western University), Daniel Finlay(Institute for Neurodegenerative Disorders), Paul A. Garcia(University of California, San Francisco), Kenneth D. Laxer(California Pacific Medical Center)
Cited by 69
Related Papers
A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease
|Neurology|2009|741
11C-PiB PET assessment of change in fibrillar amyloid-β load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study
|The Lancet Neurology|2010|696
Altered bile acid profile associates with cognitive impairment in Alzheimer's disease—An emerging role for gut microbiome
|Alzheimer s & Dementia|2018|690